Combating atherosclerosis with LXRα and PPARα agonists: Is rational multitargeted polypharmacy the future of therapeutics in complex diseases?

Molecular Interventions

Volumn 4, Issue 5, 2004, Pages 254-258

  Kino, Tomoshige ^a   Chrousos, George P ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

22 HYDROXYCHOLESTEROL; 25 HYDROXYCHOLESTEROL; ACETYL COENZYME A; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; CHOLESTEROL; CLOFIBRATE; FATTY ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; ICOSANOID; LIPID; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR ALPHA AGONIST; LIVER X RECEPTOR BETA; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIRINIXIC ACID; RETINOID X RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AORTA ANEURYSM; ATHEROSCLEROSIS; BRAIN INFARCTION; BRAIN ISCHEMIA; CARCINOGENESIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; DIET THERAPY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; GENETIC TRANSCRIPTION; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; LIPID METABOLISM; NONHUMAN; POLYPHARMACY; QUALITY OF LIFE; REVIEW;

ANIMALS; ATHEROSCLEROSIS; DNA-BINDING PROTEINS; HUMANS; POLYPHARMACY; PPAR ALPHA; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 7244240814     PISSN: 15340384     EISSN: None     Source Type: Journal    
DOI: 10.1124/mi.4.5.5     Document Type: Review

References (24)

1. Doelle, G.C. The clinical picture of metabolic syndrome. An update on this complex of conditions and risk factors. Postgrad. Med. 116, 30-38 (2004).
2. Sanders, M. Molecular and cellular concepts in atherosclerosis. Pharmacol. Ther. 61, 109-153 (1994).
3. Mantell, G. Lipid lowering drugs in atherosclerosis - the HMG-CoA reductase inhibitors. Clin. Exp. Hypertens. A 11, 927-941 (1989).
4. Vainio, S. and Ikonen, E. Macrophage cholesterol transport: a critical player in foam cell formation. Ann. Med. 35, 146-155 (2003).
5. Chiang, J.Y. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr. Rev. 23, 443-463 (2002).
6. Repa, J.J. and Mangelsdorf, D.J. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu. Rev. Cell Dev. Biol. 16, 459-481 (2000).
7. Repa, J.J. and Mangelsdorf, D.J. The liver X receptor gene team: Potential new players in atherosclerosis. Nat. Med. 8, 1243-1248 (2002).
8. Tontonoz, P. and Mangelsdorf, D.J. Liver X receptor signaling pathways in cardiovascular disease. Mol. Endocrinol. 17, 985-993 (2003).
9. Jiang, X.C., Beyer, T.P., Li, Z. et al. Enlargement of high density lipoprotein in mice via liver X receptor activation requires apolipoprotein E and is abolished by cholesteryl ester transfer protein expression. J. Biol. Chem. 278, 49072-49078 (2003).
10. Schultz, J.R., Tu, H., Luk, A. et al. Role of LXRs in control of lipogenesis. Genes Dev. 14, 2831-2838 (2000).
11. Beyer, T.P., Schmidt, R.J., Foxworthy, P. et al. Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-a agonist in Mice: Effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo. J. Pharmacol. Exp. Ther. 309, 861-868 (2004).
12. Bocher, V., Pineda-Torra, I., Fruchart, J.C., and Staels, B. PPARs: Transcription factors controlling lipid and lipoprotein metabolism. Ann. N. Y. Acad. Sci. 967, 7-18 (2002).
13. Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., and Fruchart, J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98, 2088-2093 (1998).
14. Juvet, L.K., Andresen, S.M., Schuster, G.U. et al. On the role of liver X receptors in lipid accumulation in adipocytes. Mol. Endocrinol. 17, 172-182 (2003).
15. Tobin, K.A., Steineger, H.H., Alberti, S., Spydevold, O., Auwerx, J., Gustafsson, J.A., and Nebb, H.I. Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-alpha. Mol. Endocrinol. 14, 741-752 (2000).
16. Ou, J., Tu, H., Shan, B., Luk, A., DeBose-Boyd, R.A., Bashmakov, Y., Goldstein, J.L., and Brown, M.S. Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR. Proc. Nad. Acad. Sci. U.S.A. 98, 6027-6032 (2001).
17. Pawar, A., Xu, J., Jerks, E., Mangelsdorf, D.J., and Jump, D.B. Fatty acid regulation of liver X receptors (LXR) and peroxisome proliferator-activated receptor alpha (PPARalpha) in HEK293 cells. J. Biol. Chem. 277, 39243-39250 (2002).
18. Thomas, J., Bramlett, K.S., Montrose, C. et al.A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARα) versus liver X receptor. J. Biol. Chem. 278, 2403-2410 (2003).
19. Yoshikawa, T., Ide, T., Shimano, H. et al. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling. Mol. Endocrinol. 17, 1240-1254 (2003).
20. Ide, T., Shimano, H., Yoshikawa, T. et al. Cross-talk between peroxisome proliferator-activated receptor (PPAR) a and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling. Mol. Endocrinol. 17, 1255-1267 (2003).
21. Laffitte, B.A., Joseph, S.B., Walczak, R., Pei, L., Wilpitz, D.C., Collins, J.L., and Tontonoz, P. Autoregulation of the human liver X receptor alpha promoter. Mol. Cell. Biol. 21, 7558-7568 (2001).
22. Holden, P.R. and Tugwood, J.D. Peroxisome proliferator-activated receptor a: Role in rodent liver cancer and species differences. J. Mol. Endocrinol. 22, 1-8 (1999).
23. Chrousos, G.P. The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: Neuro-endocrine and target tissue-related causes. Int. J. Obes. Relat. Metab. Disord. 24 Suppl 2, S50-S55 (2000).
24. Chrousos, G.P. The glucocorticoid receptor gene, longevity, and the complex disorders of Western societies. Am. J. Med. 117 204-207 (2004).